To examine the clinical potential of ALDH1 inhibition in cisplatin resistant lung cancer, CisR sublines were treated with low-doses (0.25μM) of Disulfiram, a potent FDA-approved ALDH inhibitor, together with equimolar copper chloride (CuCl2). Here, ALDH1A1 is linked to lung carcinoma.